Recent studies, including those by Llamas-Velasco et al. and Trpkov et al., have suggested that immunohistochemical testing for FH and its downstream product, S-(2succinyl) cysteine (2-SC), may be a viable screening method for HLRCC in cases of cutaneous leiomyomatosis and uterine leiomyomatosis and in certain high grade renal carcinomas, with results suggesting HLRCC (loss of FH and positive 2-SC) prompting more expensive confirmatory germline mutation testing [5, 13]. Here, FH is linked to hereditary leiomyomatosis and renal cell cancer.